Exome Sequencing Deciphers Rare Diseases  by Maxmen, Amy
Leading Edge
AnalysisExome Sequencing Deciphers
Rare DiseasesTwo years ago, NIH’s Undiagnosed Diseases Program began
delivering genomics to the clinic on an unprecedented scale.
Now, with 128 exomes sequenced and 39 rare diseases diag-
nosed, the program’s success is paving the way for widespread
personal genomics while pioneering new techniques for reigning
in the ‘‘tsunami’’ of genomics data.In 2009, a healthy Colombian couple
watched their two sons suffer from a
mysterious neurological illness, featuring
seizures, tremors, and other complica-
tions. When the younger son succumbed
to the illness at age 13, the family
decided to try a new approach. They
enrolled their elder son, who will be
referred to here as Carlos, in NIH’s Undi-
agnosed Diseases Program, a trans-
institute initiative dedicated to decipher-
ing the cause of rare, mysterious health
conditions.
The Undiagnosed Diseases Program at
NIH started in May 2008 as a pilot
program with initial funding of $280,000.
Since then, it has grown to include 75
physicians and scientists from almost
every institution at NIH, including endocri-
nologists, immunologists, oncologists,
and cardiologists. The team now works
together on 300 cases with $3.5 million
in funding each year.
What sets the program apart from other
large clinical projects is their state-of-the-
art genetic analyses. The team’s Illumina
platforms can sequence the entire
exome—that is, the 180,000 exons in thehuman genome—of a patient and his
family in only 9 weeks. In addition,
high-resolution microarrays can genotype
a million single-nucleotide polymor-
phisms (SNPs) for each family member,
providing information about the remaining
99%of the genome—the introns and non-
coding regions. In this way, the Un-
diagnosed Diseases Program is leading
the charge in bringing genomics to the
clinic.
So why is this type of clinical genomics
not routinely available outside the NIH?
Although the price of sequencing has
dropped to roughly $15,000 per genome
or about $3000 for an exome, data
storage and the ensuing analysis remains
too costly, too laborious, and frankly
too inefficient to put into common prac-
tice in the clinic. It’s cheap and fast to
sequence, but to glean diagnostic infor-
mation from the data is still quite laborious
and costly.
But recent successes by the Un-
diagnosed Diseases Program are shifting
this trend. First, the program is learning
how to identify patients who might benefit
most from genomic analysis. Second, theCell 1team has developed tools for quickly nar-
rowing down the flood of genomics data
to a handful of candidate genes for func-
tional tests. With these new strategies,
the program has made 39 diagnoses,
including the team’s first reported
discovery of a new disease, which was
published last month in The New England
Journal of Medicine.
Through the program, ‘‘scientists and
clinicians will get an understanding of
the difficulties involved in next-gen
sequencing, as well as the benefits; of
what cases are appropriate for genomic
study and of what filters should be applied
to the data, ‘‘ says William Gahl, the
program’s director and clinical director
of the National Human Genome Research
Institute.
Family Matters First
Before Carlos and his family arrived at the
NIH Clinical Center, their first major hurdle
was acceptance into the program. The
NIH has received 4600 inquiries for the
program and 1700 applications, but it
has enrolled only 380 cases. In general,
the program selects patients whose mal-
adies appear genetic in origin, based on
their family history or a sign that their
symptoms have a shared underlying
cause.
Typically, the NIH team first attempts
to diagnose illnesses by looking for
known genetic markers and using
standard molecular and biochemical
tests that are commercially available.
However, if they have no good leads on
the disease and therefore no candidate
genes to search for, they’ll look to a
patient’s whole exome. An entire exome
yields an overload of information,
however, and must be carefully edited.
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20,000 places, explains Thomas Mar-
kello, a clinician involved with the
program at NHGRI. This vast variation
makes it nearly impossible to find 1–2
rare alleles underlying a mysterious
disease. In other words, the nucleotide
haystack is just too big.
After some trial-and-error, the team has
developed a strategy to quickly shrink the
haystack: they eliminate many variants by
comparing the patient’s DNA with
genomic information from the family.
This added information enhances the
signal-to-noise ratio and allows them to
reduce the number of candidate genes.
‘‘Data reduction is pretty much every-
thing,’’ Markello says.
‘‘It’s simply not worth doing whole
exome sequencing on a single indi-
vidual,’’ says Gahl, ‘‘when the clinical
manifestations don’t point to a specific
group of genes.’’ With family information,
the team can apply classical pedigree
tools reminiscent of population genetics
in the 1970s to filter out mutations that
don’t follow predicted modes of Mende-
lian inheritance. And DNA from healthy
family members allows them to eliminate
harmless variations that run in the family
but don’t lead to the disease.
‘‘Family data makes a fundamental
difference,’’ says David Adams, an
NHGRI clinician who worked on Carlos’s
case. ‘‘You don’t just need family history;
we’ve learned you need family DNA to
succeed.’’
So for Carlos’s case, the geneticists
sequenced his exome, as well as that
of his parents and his deceased brother.
In general, the team gets 88% of
the complete exome with 99.9% confi-
dence. The exome data from Carlos
and his family initially generated
120,000 variants for programgeneticists
to sift through. Remarkably, the team then
narrowed this list to three candidate genes
using a series of software programsdevel-
oped internally at the NIH.
The geneticists first align the patient’s
exome with a reference sequence (typi-
cally the one generated in the Human
Genome Project) and exclude unlikely
candidate mutations according to a kill-
list of variants present in more than 1%
of exomes and genomes stored in data-
bases from two separate projects, NIH’s
ClinSeq and the 1000 Genomes Project.
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For example, a mutation encoding a
stop codon is considered more severe
than one with no effect on the resulting
amino acid.
Another in-house software program
then eliminates mutations if their inheri-
tance pattern doesn’t match that of the
disease. For example, Carlos’s disease
appeared to follow a recessive mode of
inheritance, and thus, his team kept only
the variants that behaved accordingly.
Finally, the team exports the results to
their program VarSifter, which lists the
candidate variants in order from least to
most likely.
Currently, some of this software is avail-
able to the scientific community, and ac-
cording to NHGRI’s Nancy Hansen, the
entire suitemay be released once it’s opti-
mized so that clinicians and scientists
might follow the lead of the Undiagnosed
Diseases Program.
Success Stories Accumulating
Although the program’s strategy is still
evolving, this ‘‘whittling down’’ approach
is producing results. At the end of 2010,
the program identified the root of Carlos’s
neurological symptoms, and a report on
the teen’s diagnosis is pending publica-
tion. And data from the Undiagnosed
Diseases Program team also helped
Manfred Boehm at the National Heart,
Lung and Blood Institute quickly locate
the mutation behind a mysterious
vascular calcification disorder. The team
handed him a list of 100 candidate genes,
and within 1 month he had pinpointed
mutations in the NT5E gene as the causal
culprit.
NT5E encodes a membrane-bound
nucleotidase involved in extracellular
ATP metabolism. Boehm’s study identi-
fied in three families numerous mutations,
which destroy the activity of the nucleo-
tidase. By targeting this enzyme, clini-
cians may soon be able to treat a disease
that didn’t even have a name a few
months ago. The study was published
last month in The New England Journal
of Medicine.
In contrast, Boehm says, a couple of
years ago, NIH geneticists handed him a
list of 2000 genes potentially
underlying a known disorder, and a year
passed before he could identify the causal
mutation.nc.Thus far, the program has diagnosed
39 cases—3 of which are neurological
and muscular diseases discovered
through exome analysis. Another 3
were discovered with SNP analysis,
whereas the remaining cases were
diagnosed with commercial tests,
including the identification of the rare
disease congenital disorder of glycosyla-
tion type 2B.
The Undiagnosed Diseases team also
counts concise lists of candidate muta-
tions as partial successes. These ‘‘short
lists’’ are handed off to bench scientists
for functional studies on how the
mutations contribute to disease. Right
now, these collaborations are currently
all within the NIH. But program leaders
say they’ll work with basic researchers
outside of the NIH once they’ve
established a portal for collaboration.
Marjan Huizing, a metabolic disorders
researcher at NHGRI, is not involved
with the program but says she’s ‘‘piggy-
backing’’ off their exomic techniques.
She studies endocytic trafficking defects
that lead to albinism, bleeding, and infec-
tions.
Traditional candidate gene approaches
have frustrated her team. They spent
12 years screening patients for candidate
genes and never found the right one. So
she decided to follow in the program’s
lead and analyze the exomes of three
patients. Right off the bat, she identified
the causal mutation underlying two of
the cases. For the third, more difficult
case, she’s planning to sequence the
patient’s parents.
In the meantime, geneticists are
keeping an eye on the program for clues
about the nature of rare diseases and
whether sequencing alone can identify
‘‘medically actionable alleles,’’ says Har-
vard genomicist George Church. ‘‘If that
turns out to be true, it’s a paradigm shift.’’
Although the clinicians at the Undiag-
nosed Diseases Program echo Church’s
curiosity, they keep the focus tightly on
their patients. The thrill of a diagnosis
through genomics is a triumph for
scientists and clinicians, but it means
even more to patients and their loved
ones, who have sought explanations for
years.
Still, it is a bittersweet success. Carlos
now has a name to call his malady, but
there remains no cure or powerful drug
to combat it. ‘‘Evenwhenweget lucky, the
best we can do is offer hope to the patient
that down the road, someone might usethe diagnosis to develop a treatment,’’
says John Gallin, director of the NIH Clin-
ical Center. ‘‘Our patients have referredCell 1to this as the House of Hope, but from
the perspective of a care provider, I wish
I could do even more.’’Amy Maxmen
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